BELESALA

Serial Number 79273317
Registration 6182097
700

Registration Progress

Application Filed
Sep 10, 2019
Under Examination
Approved for Publication
Aug 11, 2020
Published for Opposition
Aug 11, 2020
Registered
Oct 27, 2020

Basic Information

Serial Number
79273317
Registration Number
6182097
Filing Date
September 10, 2019
Registration Date
October 27, 2020
Published for Opposition
August 11, 2020
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
700
Status Date
Oct 27, 2020
Registration
Registered
Classes
005 010

Rights Holder

Mallinckrodt Pharmaceuticals Ireland Limited

77
Address
College Business & Technology Park,
Cruiserath Road, Blanchardstown, Dubli
IE

Ownership History

Mallinckrodt Pharmaceuticals Ireland Limited

Original Applicant
77
IE

Mallinckrodt Pharmaceuticals Ireland Limited

Owner at Publication
77
IE

Mallinckrodt Pharmaceuticals Ireland Limited

Original Registrant
77
IE

Legal Representation

Attorney
Carlynn Ferguson

USPTO Deadlines

Next Deadline
476 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-10-27)
Due Date
October 27, 2026
Grace Period Ends
April 27, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

29 events
Date Code Type Description
Jan 21, 2024 NREP P NEW REPRESENTATIVE AT IB RECEIVED
Apr 4, 2021 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 11, 2021 XXCR P GENERIC MADRID TRANSACTION CREATED
Feb 11, 2021 XXSS O GENERIC MADRID TRANSACTION SENT TO IB
Jan 27, 2021 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 27, 2020 R.PR A REGISTERED-PRINCIPAL REGISTER
Aug 11, 2020 PUBO A PUBLISHED FOR OPPOSITION
Aug 11, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 7, 2020 GPNX P NOTIFICATION PROCESSED BY IB
Jul 22, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 22, 2020 OP2R P NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jul 22, 2020 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 7, 2020 CNEA R EXAMINERS AMENDMENT -WRITTEN
Jul 7, 2020 GNEA O EXAMINERS AMENDMENT E-MAILED
Jul 7, 2020 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 7, 2020 XAEC I EXAMINER'S AMENDMENT ENTERED
Jul 7, 2020 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 6, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 6, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 6, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 8, 2020 RFNT P REFUSAL PROCESSED BY IB
Jan 21, 2020 RFRR P REFUSAL PROCESSED BY MPU
Jan 21, 2020 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 12, 2019 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 11, 2019 DOCK D ASSIGNED TO EXAMINER
Dec 11, 2019 CNRT R NON-FINAL ACTION WRITTEN
Dec 10, 2019 MAFR O APPLICATION FILING RECEIPT MAILED
Dec 6, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 5, 2019 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of neurological diseases and disorders, nephrotic diseases, endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases and disorders, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous state, gastrointestinal diseases, hepatic diseases and disorders, biliary diseases and disorders, renal disorders, cardiovascular and lipid-related diseases and disorders, inflammatory and autoimmune diseases and disorders; intravenous analgesics and antipyretics; syringes sold prefilled with pharmaceutical preparations for the treatment of neurological diseases and disorders, nephrotic diseases, endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases and disorders, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous state, gastrointestinal diseases, hepatic diseases and disorders, biliary diseases and disorders, renal disorders, cardiovascular and lipid-related diseases and disorders, inflammatory and autoimmune diseases and disorders, and intravenous analgesics and antipyretics
First Use Anywhere: 0
First Use in Commerce: 0
Class 010
Medical apparatus and instruments for use in connection with the administration of gases to patients for medical and therapeutic purposes and accessories and parts thereof, namely, medical and therapeutic gas delivery systems comprised primarily of gas cylinders, valves, regulators, flow meters, delivery hoses and apparatus and instruments for setting, measuring and regulating the mixture of medical and therapeutic gases delivered to patients; therapeutic medical device and accessories and parts thereof for extracting blood from the body, separating blood, treating it extracorporally, and returning it to the body used for extracorporeal photopheresis, extracorporeal photo immune therapy, extracorporeal photo chemotherapy, and cellular therapies; medical device, namely, medical syringes used for manual injection
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005 010